Prospects for COVID 19 Medicines - Ivor O'Shea (SAI Healthcare Committee).

preview_player
ะŸะพะบะฐะทะฐั‚ัŒ ะพะฟะธัะฐะฝะธะต
๐—˜๐˜ƒ๐—ฒ๐—ป๐˜ ๐—ง๐˜†๐—ฝ๐—ฒ: Webinar
๐——๐—ฎ๐˜๐—ฒ: Friday: 1st May, 2020

๐—ฆ๐—ฝ๐—ฒ๐—ฎ๐—ธ๐—ฒ๐—ฟ๐˜€/๐—ฃ๐—ฟ๐—ฒ๐˜€๐—ฒ๐—ป๐˜๐—ฒ๐—ฟ๐˜€:
๐‘ƒ๐‘Ÿ๐‘’๐‘ ๐‘’๐‘›๐‘ก๐‘’๐‘Ÿ: Ivor Oโ€™Shea (SAI Healthcare Committee).
๐ถโ„Ž๐‘Ž๐‘–๐‘Ÿ: Brendan McCarthy (SAI Healthcare Committee).

๐——๐—ฒ๐˜€๐—ฐ๐—ฟ๐—ถ๐—ฝ๐˜๐—ถ๐—ผ๐—ป: This online presentation considers the prospects, risks and timelines for vaccines and other medicines to prevent and/or treat COVID-19. In particular, the presentation will cover some aspects that have not, to date, featured prominently in the public debate on this virus. This presentation should be of interest to all actuaries.

๐—–๐—ผ๐—ป๐˜๐—ฒ๐—ป๐˜๐˜€: 1. Short biotech primer; 2. Prospects for vaccines; 3. Prospects for antivirals; 4. Prospects for antibodies; 5. Prospects for โ€˜repurposedโ€™ drugs; and 6. Future Scenarios & Conclusion.

๐—ฆ๐—ฝ๐—ฒ๐—ฎ๐—ธ๐—ฒ๐—ฟ ๐—•๐—ถ๐—ผ๐—ด๐—ฟ๐—ฎ๐—ฝ๐—ต๐—ถ๐—ฐ๐—ฎ๐—น ๐—ฑ๐—ฒ๐˜๐—ฎ๐—ถ๐—น๐˜€: Over the past decade, Ivor has invested in over 475 listed biotech companies. Over one third of these biotechs developed medicines for infectious diseases. As a result, Ivor has accumulated practical experience in assessing the prospects and timelines for potential new medicines. Ivor is a member of the Societyโ€™s Healthcare Committee.
ะ ะตะบะพะผะตะฝะดะฐั†ะธะธ ะฟะพ ั‚ะตะผะต